Your session is about to expire
← Back to Search
Open label trial of suvorexant in individuals with alcohol use disorder for Cushing's Syndrome (Suvsubuse Trial)
Suvsubuse Trial Summary
This trial will determine if the orexin 1 / 2 receptor antagonist suvorexant decreases sleep disturbance and drug craving in patients with substance use disorders (SUDs), and if it has the potential to reduce relapse rates.
- Cushing's Syndrome
- Craving
- Sleep Disorder
Suvsubuse Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Suvsubuse Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history of narcolepsy or experiencing unusual events during sleep.You have difficulty making decisions or understanding information.You have thoughts of hurting yourself or have tried to hurt yourself in the past.You stopped using opioid drugs with the help of a doctor at least five days ago, and you are having trouble sleeping even with your current sleep medications.You have ongoing breathing problems like asthma or COPD that can disrupt your sleep at night.
- Group 1: Open label trial of suvorexant in individuals with alcohol use disorder
- Group 2: Open label trial of suvorexant in individuals with opioid use disorder
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any unfilled vacancies for participants in this experiment?
"Unfortunately, this study is not recruiting at the moment. Although, it's worth noting that the trial was most recently updated on July 12th, 2022 and originally posted on July 1st, 2019. If you're looking for similar studies, 516 trials are currently enrolling patients with cravings and 14 are seeking participants for this treatment."
Are people over the age of 35 eligible to participate in this trial?
"As long as potential patients are aged between 21 and 64, they will be eligible for this clinical trial."
How many people are being treated with this experimental medication?
"Unfortunately, this particular trial is no longer searching for patients to enroll. Although, if you are still interested in participating in a study, there are 516 other trials actively looking for participants with your condition and 14 other studies testing this treatment that are also currently recruiting."
Is this a new or innovative treatment, or has it been studied before?
"There are currently 14 ongoing clinical trials testing this potential treatment. Out of these, 2 have progressed to Phase 3. The vast majority of trial locations for this study are situated in Silver Spring, Maryland; however, there are 71 total sites running these experiments."
Who meets the eligibility requirements for this clinical trial?
"This trial is looking for 28 participants who have cravings and meet the following criteria: Caron Foundation residential alcohol or opioid dependent patients that have a history of daily or near daily substance use for the month prior to admittance, Group 2: at least five days post medically assisted withdrawal for opioid dependence and complain of problems falling asleep, remaining asleep after sleep onset, or poor sleep quality on current sleep medication (antidepressant/melatonin), Sex: male or female, Age: 21-64 (inclusive) years old."
Share this study with friends
Copy Link
Messenger